OctoPlus N.V. has signed a new drug delivery technology evaluation contract for two compounds with a European biotech company. Under the contract, OctoPlus will evaluate the feasibility of two controlled release formulations that combine the active ingredients of the client's compounds with OctoPlus' drug delivery technology. If the evaluations are successful, the contract may progress to a full process development, manufacturing and licensing agreement.